What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide investors with unaudited pro forma condensed combined financial information for the fiscal year ended December 29, 2007. This information illustrates how the company would have performed financially had the merger with Caremark Rx, Inc. occurred at the beginning of that fiscal year.

Why are these financial results 'pro forma' and not actual historical results?

These are pro forma results because the merger with Caremark was completed on March 22, 2007. The pro forma statements are hypothetical, showing the combined company's financial performance as if the merger had been in place for the entire fiscal year 2007. They are intended to give investors a better understanding of the combined entity's potential financial scale and performance post-merger, but they are not actual historical financial statements of the combined company for that period.

What major adjustments were made in the pro forma statements?

Key adjustments include eliminating inter-company revenues between CVS pharmacies and Caremark's PBM services ($941.5 million), recording new depreciation and amortization expenses on acquired intangible assets ($37.1 million), and adjusting interest expense and income tax provisions to reflect the combined entity. Importantly, costs related to the merger itself (e.g., advisory fees) and potential future cost savings from integration were excluded.

Does this pro forma information include any anticipated cost savings from the merger?

No, the unaudited pro forma combined results of operations explicitly do not include any cost savings that may result from the combination of CVS and Caremark, nor do they include any estimated costs that will be incurred by the company to integrate the businesses. These aspects would be detailed in future filings as they materialize.

CVS 8-K SEC Disclosure

Summary

This 8-K filing from CVS Health Corp. (now CVS Caremark Corporation) provides unaudited pro forma condensed combined financial information for the fiscal year ended December 29, 2007, illustrating the financial impact of the merger with Caremark Rx, Inc. which was completed in March 2007. The pro forma data is presented for informational purposes and is not a reflection of actual historical results. It's crucial for investors to understand that this information is forward-looking and illustrative, and should be reviewed alongside the company's audited financial statements for a complete picture. The key takeaway is the combined entity's projected revenue and earnings based on the merger's initial impact. The pro forma statements show significant adjustments, including the elimination of inter-company revenues and the recognition of new depreciation and amortization expenses related to the acquired intangible assets. It's important to note that these pro forma results do not include any anticipated cost savings from integration or any integration costs themselves, which will be detailed in future filings.

Key Highlights

1The filing presents unaudited pro forma financial statements for CVS Caremark Corporation for the fiscal year ended December 29, 2007, reflecting the merger with Caremark Rx, Inc. completed in March 2007.
2Pro forma net revenue for the combined entity is presented at $83.8 billion, an increase from CVS's historical standalone revenue, demonstrating the scale of the merger.
3Significant pro forma adjustments include the elimination of $941.5 million in inter-company revenues between CVS retail and Caremark's pharmacy benefit management (PBM) operations.
4New depreciation and amortization expenses of $37.1 million are recognized, primarily related to identifiable intangible assets such as customer contracts, relationships, and trade names acquired in the merger.
5Pro forma net earnings for the combined company are reported at $2.9 billion, with diluted earnings per share of $1.92.
6The pro forma financial information explicitly excludes any potential cost savings from integration or any integration costs incurred by the combined company.
7Certain one-time merger-related costs and stock option expenses from Caremark are also excluded from the pro forma combined results, providing a cleaner view of the ongoing operational impact.

CVS HEALTH Corp 8-K Report, Corporate Update (Sep 5, 2008)

Summary

Key Highlights

Frequently Asked Questions